A single dose of the topical carbonic anhydrase inhibitor MK-927 decreases IOP in patients

• Published in: British journal of ophthalmology Vol. 74; no. 7; pp. 405 - 408
• Main Authors: Pfeiffer, N, Hennekes, R, Lippa, E A, Grehn, F, Garus, H, Brunner-Ferber, F L
• Format: Journal Article
• Language: English
• Published: BMA House, Tavistock Square, London, WC1H 9JR BMJ Publishing Group Ltd 01-07-1990; BMJ; BMJ Publishing Group LTD
• Subjects: Biological and medical sciences; Carbonic Anhydrase Inhibitors - administration & dosage; Carbonic Anhydrase Inhibitors - therapeutic use; Double-Blind Method; Eye; Female; Glaucoma, Open-Angle - drug therapy; Humans; Intraocular Pressure - drug effects; Male; Medical sciences; Ocular Hypertension - drug therapy; Pharmacology. Drug treatments; Randomized Controlled Trials as Topic; Sulfonamides - administration & dosage; Sulfonamides - therapeutic use; Thiophenes - administration & dosage; Thiophenes - therapeutic use; Eye drop; Human; Chemotherapy; Eye disease; Treatment; Carbonic anhydrase; Open angle glaucoma; Single dose; Ocular hypertension; Enzyme inhibitor
• ISSN: 0007-1161; 1468-2079
• DOI: 10.1136/bjo.74.7.405

MK-927 is a novel topical carbonic anhydrase inhibitor (CAI). We present the first single-dose clinical trial of MK-927 in 24 patients with bilateral primary open-angle glaucoma or ocular hypertension. This investigation was conducted as a two-centre, double-masked, randomised, placebo controlled study. Patients received one drop of 2% MK-927 in one eye and placebo in the other eye. Modified diurnal intraocular pressure (IOP) curves were performed before the study and on one treatment day. A single dose of 2% MK-927 induced a peak mean IOP decrease of 10.5 mmHg at 4.5 hours postdose. With compensation for diurnal variation, as determined by the prestudy diurnal pressure curve, the net peak mean reduction of IOP caused by MK-927 was 7.5 mmHg versus a corresponding net change of 1.4 mmHg in the contralateral placebo treated eye. Thus a single dose of MK-927 gave a clinically significant IOP reduction in patients.